279 related articles for article (PubMed ID: 29468438)
1. Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.
Ross DM; Masszi T; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; Garcia-Gutierrez V; Gattermann N; le Coutre PD; Martino B; Saussele S; Giles FJ; Radich JP; Saglio G; Deng W; Krunic N; Bédoucha V; Gopalakrishna P; Hochhaus A
J Cancer Res Clin Oncol; 2018 May; 144(5):945-954. PubMed ID: 29468438
[TBL] [Abstract][Full Text] [Related]
2. Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
Radich JP; Hochhaus A; Masszi T; Hellmann A; Stentoft J; Casares MTG; García-Gutiérrez JV; Conneally E; le Coutre PD; Gattermann N; Martino B; Saussele S; Giles FJ; Ross DM; Aimone P; Li S; Titorenko K; Saglio G
Leukemia; 2021 May; 35(5):1344-1355. PubMed ID: 33707652
[TBL] [Abstract][Full Text] [Related]
3. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
Hochhaus A; Masszi T; Giles FJ; Radich JP; Ross DM; Gómez Casares MT; Hellmann A; Stentoft J; Conneally E; García-Gutiérrez V; Gattermann N; Wiktor-Jedrzejczak W; le Coutre PD; Martino B; Saussele S; Menssen HD; Deng W; Krunic N; Bedoucha V; Saglio G
Leukemia; 2017 Jul; 31(7):1525-1531. PubMed ID: 28218239
[TBL] [Abstract][Full Text] [Related]
4. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.
Mahon FX; Boquimpani C; Kim DW; Benyamini N; Clementino NCD; Shuvaev V; Ailawadhi S; Lipton JH; Turkina AG; De Paz R; Moiraghi B; Nicolini FE; Dengler J; Sacha T; Takahashi N; Fellague-Chebra R; Acharya S; Wong S; Jin Y; Hughes TP
Ann Intern Med; 2018 Apr; 168(7):461-470. PubMed ID: 29459949
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update.
Hughes TP; Clementino NCD; Fominykh M; Lipton JH; Turkina AG; Moiraghi EB; Nicolini FE; Takahashi N; Sacha T; Kim DW; Fellague-Chebra R; Tiwari R; Bouard C; Mahon FX
Leukemia; 2021 Jun; 35(6):1631-1642. PubMed ID: 33980976
[TBL] [Abstract][Full Text] [Related]
6. Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis.
Berdeja JG; Heinrich MC; Dakhil SR; Goldberg SL; Wadleigh M; Kuriakose P; Cortes J; Radich J; Helton B; Rizzieri D; Paley C; Dautaj I; Mauro MJ
Leuk Lymphoma; 2019 Oct; 60(10):2384-2393. PubMed ID: 30912699
[TBL] [Abstract][Full Text] [Related]
7. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akin G; Dag IM; Ilhan O
Hematology; 2018 Dec; 23(10):771-777. PubMed ID: 29996726
[TBL] [Abstract][Full Text] [Related]
8. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.
Saydam G; Haznedaroglu IC; Kaynar L; Yavuz AS; Ali R; Guvenc B; Akay OM; Baslar Z; Ozbek U; Sonmez M; Aydin D; Pehlivan M; Undar B; Dagdas S; Ayyildiz O; Akkaynak DZ; Dag IM; Ilhan O
Expert Opin Pharmacother; 2016 Oct; 17(14):1851-8. PubMed ID: 27501474
[TBL] [Abstract][Full Text] [Related]
9. U.S. Food and Drug Administration Benefit-Risk Assessment of Nilotinib Treatment Discontinuation in Patients with Chronic Phase Chronic Myeloid Leukemia in a Sustained Molecular Remission.
Pulte ED; Wroblewski T; Bloomquist E; Tang S; Farrell A; Deisseroth A; McKee AE; Pazdur R
Oncologist; 2019 May; 24(5):e188-e195. PubMed ID: 31019020
[TBL] [Abstract][Full Text] [Related]
10. CML patients with deep molecular responses to TKI have restored immune effectors and decreased PD-1 and immune suppressors.
Hughes A; Clarson J; Tang C; Vidovic L; White DL; Hughes TP; Yong AS
Blood; 2017 Mar; 129(9):1166-1176. PubMed ID: 28049640
[TBL] [Abstract][Full Text] [Related]
11. De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.
Clark RE; Polydoros F; Apperley JF; Milojkovic D; Rothwell K; Pocock C; Byrne J; de Lavallade H; Osborne W; Robinson L; O'Brien SG; Read L; Foroni L; Copland M
Lancet Haematol; 2019 Jul; 6(7):e375-e383. PubMed ID: 31201085
[TBL] [Abstract][Full Text] [Related]
12. Switching to nilotinib is associated with deeper molecular responses in chronic myeloid leukemia chronic phase with major molecular responses to imatinib: STAT1 trial in Japan.
Noguchi S; Nakaseko C; Nishiwaki K; Ogasawara H; Ohishi K; Tokuhira M; Noguchi M; Kimura H; Handa H; Mitani K; Miura M; Wakita H; Takahashi N;
Int J Hematol; 2018 Aug; 108(2):176-183. PubMed ID: 29713954
[TBL] [Abstract][Full Text] [Related]
13. [Observational study of chronic myeloid leukemia Chinese patients who discontinued tyrosine kinase inhibitors in the real-world].
Zhao HF; Yang YF; Liu BC; Li WM; Xu N; Liu XL; Jiang Q; Dang HB; Liang LX; Zhang Y; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2022 Aug; 43(8):636-643. PubMed ID: 36709147
[No Abstract] [Full Text] [Related]
14. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Hochhaus A; Rosti G; Cross NC; Steegmann JL; le Coutre P; Ossenkoppele G; Petrov L; Masszi T; Hellmann A; Griskevicius L; Wiktor-Jedrzejczak W; Rea D; Coriu D; Brümmendorf TH; Porkka K; Saglio G; Gastl G; Müller MC; Schuld P; Di Matteo P; Pellegrino A; Dezzani L; Mahon FX; Baccarani M; Giles FJ
Leukemia; 2016 Jan; 30(1):57-64. PubMed ID: 26437782
[TBL] [Abstract][Full Text] [Related]
15. Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt).
Nagafuji K; Matsumura I; Shimose T; Kawaguchi T; Kuroda J; Nakamae H; Miyamoto T; Kadowaki N; Ishikawa J; Imamura Y; Yamazaki H; Akashi K; Kanakura Y
Int J Hematol; 2019 Dec; 110(6):675-682. PubMed ID: 31538327
[TBL] [Abstract][Full Text] [Related]
16. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
Rea D; Nicolini FE; Tulliez M; Guilhot F; Guilhot J; Guerci-Bresler A; Gardembas M; Coiteux V; Guillerm G; Legros L; Etienne G; Pignon JM; Villemagne B; Escoffre-Barbe M; Ianotto JC; Charbonnier A; Johnson-Ansah H; Noel MP; Rousselot P; Mahon FX;
Blood; 2017 Feb; 129(7):846-854. PubMed ID: 27932374
[TBL] [Abstract][Full Text] [Related]
17. Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
Yamazaki K; Inagaki N; Moldaver D; Viana R; Kimura S
Cancer Sci; 2020 Jul; 111(7):2526-2535. PubMed ID: 32324296
[TBL] [Abstract][Full Text] [Related]
18. Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors.
Haddad FG; Sasaki K; Issa GC; Garcia-Manero G; Ravandi F; Kadia T; Cortes J; Konopleva M; Pemmaraju N; Alvarado Y; Yilmaz M; Borthakur G; DiNardo C; Jain N; Daver N; Short NJ; Jabbour E; Kantarjian H
Am J Hematol; 2022 Jul; 97(7):856-864. PubMed ID: 35357036
[TBL] [Abstract][Full Text] [Related]
19. Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis.
Giles FJ; Rea D; Rosti G; Cross NCP; Steegmann JL; Griskevicius L; le Coutre P; Coriu D; Petrov L; Ossenkoppele GJ; Mahon FX; Saussele S; Hellmann A; Koskenvesa P; Brümmendorf TH; Gastl G; Castagnetti F; Vincenzi B; Haenig J; Hochhaus A
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1585-1596. PubMed ID: 28364360
[TBL] [Abstract][Full Text] [Related]
20. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia.
Shanmuganathan N; Pagani IS; Ross DM; Park S; Yong ASM; Braley JA; Altamura HK; Hiwase DK; Yeung DT; Kim DW; Branford S; Hughes TP
Blood; 2021 Mar; 137(9):1196-1207. PubMed ID: 32871588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]